Emmis Acquisition (EMIS) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Emmis Acquisition (EMIS) has outperformed Upstream Bio (UPB) over the past year, gaining 3.3% versus a loss of 86.8%. Emmis Acquisition is the larger company by market cap ($162.2 million vs $151.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMIS | UPB |
|---|---|---|
| Share price | $10.28 | $2.76 |
| Market cap | $162.18M | $151.17M |
| 1-day change | +0.10% | -18.10% |
| YTD return | +3.32% | -89.83% |
| 1-year return | +3.32% | -86.84% |
| EPS (TTM) | — | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.85M |
| Revenue growth (YoY) | — | +20.42% |
| Net income (latest FY) | — | $-143.44M |
| Operating margin | — | -5618.82% |
| Net margin | — | -5026.03% |
| 52-week high | $10.28 | $33.68 |
| 52-week low | $9.90 | $2.74 |
| Distance from 52-week high | 0.00% | -91.81% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1028.26% |
| Average volume | 14.46K | 734.05K |
| Shares outstanding | 11.94M | 54.77M |
| Employees | — | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EMIS has outperformed UPB by 90.2 percentage points over the past year.
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
EMIS vs UPB FAQ
Which is bigger, Emmis Acquisition or Upstream Bio?
Emmis Acquisition (EMIS) is larger, with a market capitalization of $162.18M compared with $151.17M for Upstream Bio (UPB).
Which stock has performed better over the past year, EMIS or UPB?
EMIS returned +3.32% over the past 12 months, compared with -86.84% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Emmis Acquisition and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.